Ido alluded to being able to use existing clinical data/trials/results to quicken the progress of the new technology. The way I see it is that if Auscann can prove the reproduceable exact dosage then the product may very well be fit for use/sale pretty quickly, because the use of THC and CBD trials have been done and don't need to be done again.
The trials relating to degrading of the THC and CBD over time will take longer, of course. But, if the reproduceable dosage is done, then prior to the trial for (non) degradation, the product will be in the same boat as oils are currently.
Maybe, and I am drawing my own conclusions and reading inbetween the lines.
AC8 Price at posting:
35.5¢ Sentiment: Buy Disclosure: Held
